Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis

Glatiramer acetate (GA) represents one of the most common disease-modifying therapies for multiple sclerosis. GA is currently approved for patients at high risk of developing clinically definite multiple sclerosis (CDMS) after having experienced a well-defined first clinical episode (clinically isol...

Descripción completa

Detalles Bibliográficos
Autor principal: Fernández, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619555/
https://www.ncbi.nlm.nih.gov/pubmed/23650472
http://dx.doi.org/10.4137/JCNSD.S8755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619555/
https://www.ncbi.nlm.nih.gov/pubmed/23650472
http://dx.doi.org/10.4137/JCNSD.S8755

Ejemplares similares